Disruptive menopause symptoms deserve treatment. That is the practical message behind renewed attention to hormone therapy and an updated American College of Obstetricians and Gynecologists (ACOG) guideline covering hot flashes, sleep disruption, and mood symptoms. Effective care can include hormonal and nonhormonal treatments, chosen around a woman’s symptoms, health history, and preferences. The update is an opportunity to revisit care with better information—not a reason for everyone to start hormones. [1] [2]
For women trying to work, exercise, sleep, and feel like themselves, this conversation reaches well beyond an occasional hot flash. A treatment discussion can begin with a straightforward question: Which symptoms are interfering with my life, and what can we do about them?
What is new in menopause care?
ACOG’s new clinical practice guideline evaluates drug and nondrug approaches to menopause-related vasomotor symptoms—the medical term for hot flashes and night sweats—as well as sleep and mood symptoms. It covers both perimenopause and postmenopause, including spontaneous menopause and induced menopause at or beyond age 40. Its recommendations use a structured assessment of evidence quality; some clinical guidance is provided as good practice points where evidence is insufficient for a formal recommendation. [1]
A separate regulatory change is also shaping the discussion. The FDA began revising hormone-therapy boxed warnings in November 2025 and approved labeling changes for an initial six products in February 2026. On October 30, 2026, federal officials announced updated labeling for three additional estradiol patch products. These changes remove specified cardiovascular, breast-cancer, and probable-dementia statements from the boxed-warning section for the affected products. A labeling change does not eliminate treatment risks or make every hormone product interchangeable. [3] [4]
Is hormone therapy still the most effective treatment for hot flashes?
Yes. Systemic menopausal hormone therapy remains the most effective treatment for hot flashes and night sweats. “Systemic” means hormones enter the circulation and act throughout the body. Options include pills, patches, gels, and sprays. For many eligible women with bothersome symptoms, it is a leading treatment to discuss. [2] [5]
The treatment plan also depends on whether a woman has a uterus. With systemic estrogen, a progestogen is generally needed to protect the uterine lining; certain alternative combinations provide protection differently. This is one reason the decision involves more than choosing an estrogen dose. Low-dose vaginal estrogen serves a different purpose: it treats local symptoms such as vaginal dryness and is not a substitute for systemic treatment of hot flashes. [5]
Why do age and time since menopause matter?
The balance of benefit and risk is generally more favorable for symptomatic women younger than 60 or within 10 years of menopause onset who have no contraindications. Starting later can carry greater absolute risks, including blood clots, stroke, and coronary heart disease. This timing framework supports an individual assessment; it is not a universal eligibility rule. Formulation, dose, route, duration, and medical history all matter. [2]
A history of breast or endometrial cancer, stroke, heart attack, blood clots, or liver disease can change whether systemic hormone therapy is appropriate. The right conversation includes those risks alongside symptom burden and treatment goals, with periodic reassessment rather than an assumption that the original plan should continue indefinitely. [5]
What if a woman cannot—or prefers not to—use hormones?
Nonhormonal options include selected antidepressants, gabapentin, and medicines that target neurokinin signaling involved in temperature regulation. Fezolinetant, sold as Veozah, blocks the neurokinin-3 receptor. Elinzanetant, sold as Lynkuet and approved by the FDA in October 2025, offers another prescription option for moderate to severe hot flashes. These medicines create additional treatment choices without replacing estrogen. [6] [7] [8]
Nonhormonal does not mean risk-free. Fezolinetant carries a boxed warning for rare but serious liver injury and requires liver testing before treatment and during follow-up. Elinzanetant has its own precautions, including liver testing and possible daytime impairment or sleepiness. Drug interactions and monitoring requirements should be reviewed for the specific medication. [7] [9]
Which approach addresses which problem?
| Approach | Main role | Key consideration |
|---|---|---|
| Systemic hormone therapy | Most effective treatment for hot flashes and night sweats. | Requires an individual risk assessment and appropriate protection of the uterine lining. |
| Low-dose vaginal estrogen | Treats local vaginal symptoms, including dryness. | Does not treat hot flashes throughout the body. |
| Neurokinin-targeting medicines | Provide nonhormonal treatment for hot flashes. | Have medication-specific precautions and monitoring requirements. |
| Selected antidepressants or gabapentin | Offer additional nonhormonal treatment options. | Selection depends on symptoms, other medications, and tolerability. |
| Cognitive behavioral therapy for insomnia | Improves sleep through structured behavioral strategies. | Can complement treatment of nighttime symptoms. |
Treatment options have different goals; this is not a ranking.